NUTX — Nutex Health, Inc.

Nutex Health Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $216.5 million, a 2% increase from $211.8 million in Q1 2025.
• Net Income: $46.8 million, up from $21.2 million in Q1 2025.
• Adjusted EBITDA: $57.6 million, down 21% from $72.8 million in Q1 2025, attributed to timing of IDR expenses.
• Patient Visits: 49,700 total visits, a 3.1% increase from 48,300 in Q1 2025.
• Net Long-Term Debt: Decreased from $29.2 million at year-end 2025 to $24.3 million.
• Cash from Operating Activities: Increased to $75.5 million from $51 million in Q1 2025.
• Cash on Hand: Grew to $207.3 million from $185.6 million at year-end 2025.

2. Strategic Updates and Business Highlights

• Share Repurchase Program: Completed a $25 million share repurchase and initiated a second $25 million program, reflecting management's confidence in the company's value.
• Hospital Development: Board approved direct investment in new hospital facilities, transitioning from reliance on third-party developers to internal development for cost efficiency.
• Technology Investments: Focus on AI and IT to enhance patient care and streamline operations.
• Population Health Division: Revenue increased by 14% to $8.9 million, with a strategy to build physician networks around hospitals to drive patient volume.

3. Forward Guidance and Outlook

• Expansion Plans: On track to open three additional hospitals in Q3 and Q4 2026 (San Antonio, Jacksonville, and West Little Rock).
• Revenue Growth: Anticipated stabilization in revenue metrics as the company continues to improve patient acuity and negotiate better reimbursement rates with payers.
• Effective Tax Rate: Expected to remain in the high teens to 20% range for the remainder of the year.

4. Bad News, Challenges, or Points of Concern

• Declining Adjusted EBITDA: A significant drop attributed to timing of IDR expenses, raising concerns about operational efficiency.
• Increased Arbitration Costs: Costs rose to 35% of arbitration-related revenue, higher than the historical mid-20% range, though expected to normalize in future quarters.
• Milder Flu Season Impact: A less severe flu season compared to 2025 contributed to modest patient volume growth.
• Competitive Pressures: Ongoing challenges in negotiations with payers and potential legislative changes affecting reimbursement models.

5. Notable Q&A Insights

• Hospital Development Timeline: New projects in Florida initiated, with a typical development timeline of 18-24 months before opening.
• IDR Process: Currently submitting 50-60% of claims through IDR, with a high success rate in arbitration outcomes.
• Patient Volume Growth: The modest 3% growth in patient visits attributed to new hospital openings and a less severe flu season.
• Population Health Strategy: Focus on building awareness and partnerships with local physicians to drive patient volume to Nutex facilities.

Overall, Nutex Health reported solid financial performance with strategic initiatives aimed at growth and efficiency, despite facing challenges related to arbitration costs and a milder flu season impacting patient volumes. The company remains optimistic about future developments and revenue stabilization.